Want to see SE:NXTCL full AI Analyst Report?

NextCell Pharma AB (NXTCL) Price & Analysis

1 Followers

NXTCL Stock Chart & Stats

kr0.92

kr0.02(0.56%)

At close: Mar 06 4:00 PM EST

kr0.92

kr0.02(0.56%)

Day’s Range― - ―

52-Week Rangekr0.63 - kr1.78

Previous CloseN/A

Volume77.06K

Average Volume (3M)237.08K

Market Cap

kr140.55M

Enterprise Valuekr107.45

Total Cash (Recent Filing)kr32.33M

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)―

Beta0.35

Next Earnings

Aug 27, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.43

Shares Outstanding126,392,960

10 Day Avg. Volume155,192

30 Day Avg. Volume237,081

Financial Highlights & Ratios

PEG Ratio0.13

Price to Book (P/B)1.36

Price to Sales (P/S)8.24

P/FCF Ratio-2.09

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.4

Revenue Forecast (FY)kr16.60M

Bulls Say, Bears Say

Bulls Say

Conservative Capital StructureHaving no debt materially lowers financial risk and preserves strategic optionality. Over the next 2–6 months this reduces bankruptcy and interest-service pressure, allowing management to allocate limited cash toward R&D, manufacturing scale-up or partnership building without debt covenants constraining choices.

Multi-year Revenue ExpansionSustained revenue growth over multiple years indicates product/service traction and market demand for the company’s cell-therapy offerings. This trend supports longer-term commercial viability and the ability to progress clinical programs and manufacturing operations, reducing pure early-stage development risk.

Integrated Cell Therapy CapabilitiesOwning R&D, ProTrans program expertise and manufacturing/cell-banking capabilities creates a durable operational edge. Vertical integration helps control quality, supply chain and timelines, enabling potential service revenues and faster clinical/commercial execution versus peers reliant on outsourced manufacturing.

Bears Say

High Cash BurnConsistent large negative operating and free cash flows force reliance on external funding to sustain operations. This constrains long-term program development, increases dilution risk from equity raises, and can delay clinical or commercial milestones if capital access tightens over the next several quarters.

Persistently Negative MarginsDeep, persistent negative gross profits and wide net losses indicate the business has not yet reached scalable, margin-accretive operations. Over months, this undermines free-cash-flow improvement prospects and requires either structural cost reductions, higher-margin revenue or continued financing to bridge to commercial break-even.

Eroding Equity Base / Dilution RiskA marked decline in equity over several years reflects cumulative losses and capital raises, increasing future dilution risk for shareholders. This reduces long-term per-share value unless profitability or cash generation improves, and can limit attractiveness to long-term investors dependent on low dilution.

NXTCL FAQ

What was NextCell Pharma AB’s price range in the past 12 months?

NextCell Pharma AB lowest stock price was kr0.63 and its highest was kr1.78 in the past 12 months.

What is NextCell Pharma AB’s market cap?

NextCell Pharma AB’s market cap is kr140.55M.

When is NextCell Pharma AB’s upcoming earnings report date?

NextCell Pharma AB’s upcoming earnings report date is Aug 27, 2026 which is in 25 days.

How were NextCell Pharma AB’s earnings last quarter?

NextCell Pharma AB released its earnings results on May 28, 2026. The company reported -kr0.092 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.

Is NextCell Pharma AB overvalued?

According to Wall Street analysts NextCell Pharma AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does NextCell Pharma AB pay dividends?

NextCell Pharma AB does not currently pay dividends.

What is NextCell Pharma AB’s EPS estimate?

NextCell Pharma AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does NextCell Pharma AB have?

NextCell Pharma AB has 126,392,960 shares outstanding.

What happened to NextCell Pharma AB’s price movement after its last earnings report?

NextCell Pharma AB reported an EPS of -kr0.092 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.206%.

Which hedge fund is a major shareholder of NextCell Pharma AB?

Currently, no hedge funds are holding shares in SE:NXTCL

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

NextCell Pharma AB

NextCell Pharma AB operates as a biopharmaceutical enterprise, dedicating its efforts to the groundbreaking research and advancement of novel stem cell-based therapies within Sweden. A significant development from the company is ProTrans, an investigational drug derived from stem cells, primarily formulated to address autoimmune and inflammatory ailments. Beyond therapeutic development, NextCell Pharma AB also offers Cellaviva, a specialized stem cell banking service that enables families to securely preserve stem cells sourced from umbilical cord blood and tissue. Established in 2014, the company maintains its corporate headquarters in Huddinge, Sweden.